TMDX Stock Forecast & Price Target

TransMedics Group is a compelling investment opportunity due to its innovative OCS technology, extensive clinical data, and successful implementation of its National OCS Program (NOP). Despite facing challenges with clinical trial equipment access, management remains optimistic and we believe enrollment will continue to grow in the coming months. Additionally, TMDX's recent Q4 results and guidance exceed expectations, with potential upside on the revenue line. We believe the company's continued investment in its international and kidney transplant ventures position it for significant growth in the coming years, solidifying TransMedics as a leader in the transplant therapy market.

TransMedics Group is a commercial-stage medical technology company that has developed the Organ Care System (OCS) to improve organ transplant therapy. Despite solid financial guidance and potentially beatable sales, there are concerns about a decline in operating margins due to significant investments and a reliance on data from one month for the 4Q25 estimate. Additionally, the projected EV/sales multiple of ~10.0x may be optimistic and may not be sustainable in the long-term, leading to a negative outlook on the stock.